{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:13:25Z","timestamp":1778746405138,"version":"3.51.4"},"reference-count":43,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15612","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:21:18Z","timestamp":1776860478000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant immunotherapy plus chemotherapy and maintenance immunotherapy for pulmonary lymphoepithelioma\u2011like carcinoma with hepatitis B virus infection, KRAS mutation and high expression of programmed death ligand 1: A case report"],"prefix":"10.3892","volume":"31","author":[{"given":"Jing","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Gui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Xiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"key20260514105755_b1-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1016\/j.cllc.2018.12.014","article-title":"Clinical features and prognosis of pulmonary Lymphoepithelioma-like carcinoma: Summary of Eighty-five cases","volume":"20","author":"Qin","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"key20260514105755_b2-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.lungcan.2019.09.007","article-title":"First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma","volume":"137","author":"Lin","year":"2019","journal-title":"Lung Cancer"},{"key":"key20260514105755_b3-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s12672-025-02692-z","article-title":"Role of the \u2018inflammation-immunity-abolism\u2019 network in non-small cell lung cancer: A multi-omics analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov Oncol"},{"key":"key20260514105755_b4-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/jso.26276","article-title":"Clinicopathological and prognostic analyses of 86 resected pulmonary lymphoepithelioma-like carcinomas","volume":"123","author":"Chen","year":"2021","journal-title":"J Surg Oncol"},{"key":"key20260514105755_b5-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12890-022-02097-6","article-title":"Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: A population-based, multicentre, real-world study","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Pulm Med"},{"key":"key20260514105755_b6-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.2147\/OTT.S241337","article-title":"Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-review","volume":"13","author":"Hu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"key20260514105755_b7-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"10255","DOI":"10.1038\/s41598-017-10925-7","article-title":"PD-L1 expression in lung cancer and its correlation with driver mutations: A meta-analysis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"key20260514105755_b8-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ijscr.2021.01.066","article-title":"Primary pulmonary lymphoepithelioma-like carcinoma with positive expression of Epstein-Barr virus, PD-L1: A case report","volume":"79","author":"Sasaki","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"key20260514105755_b9-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"951817","DOI":"10.3389\/fimmu.2022.951817","article-title":"PD-1\/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Immunol"},{"key":"key20260514105755_b10-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/1759-7714.13271","article-title":"Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma","volume":"11","author":"Yin","year":"2020","journal-title":"Thorac Cancer"},{"key":"key20260514105755_b11-ol-31-6-15612","first-page":"3793","article-title":"Objective assessment of WHO\/ECOG performance status","volume":"10","author":"Sok","year":"2019","journal-title":"Support Care Cancer"},{"key":"key20260514105755_b12-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/v13050877","article-title":"Pathogenic role of Epstein-Barr virus in lung cancers","volume":"13","author":"Becnel","year":"2021","journal-title":"Viruses"},{"key":"key20260514105755_b13-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.path.2019.10.003","article-title":"Lung cancer staging","volume":"13","author":"Kutob","year":"2020","journal-title":"Surg Pathol Clin"},{"key":"key20260514105755_b14-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"e0169321","DOI":"10.1128\/jvi.01693-21","article-title":"Genomic landscapes of Epstein-Barr virus in pulmonary Lymphoepithelioma-Like carcinoma","volume":"96","author":"Wu","year":"2022","journal-title":"J Virol"},{"key":"key20260514105755_b15-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"920021","DOI":"10.3389\/fimmu.2022.920021","article-title":"From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1\/PD-L1 blockades","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"key20260514105755_b16-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"e0117741","DOI":"10.1371\/journal.pone.0117741","article-title":"Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"key":"key20260514105755_b17-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jso.2930360413","article-title":"Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung","volume":"36","author":"B\u00e9gin","year":"1987","journal-title":"J Surg Oncol"},{"key":"key20260514105755_b18-ol-31-6-15612","first-page":"e70309","article-title":"Lymphoepithelial carcinoma of the lung: A case report and review of the literature","volume":"16","author":"Samaras","year":"2024","journal-title":"Cureus"},{"key":"key20260514105755_b19-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s43046-021-00103-2","article-title":"Demographics, clinical features, and prognosis of rare lymphoepithelioma-like carcinoma across different anatomic sites","volume":"34","author":"Zhai","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"key":"key20260514105755_b20-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/RTI.0000000000000070","article-title":"Primary lymphoepithelioma-like carcinoma of the lung: Distinct computed tomography features and associated clinical outcomes","volume":"29","author":"Mo","year":"2014","journal-title":"J Thorac Imaging"},{"key":"key20260514105755_b21-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","article-title":"Ki-67: More than a proliferation marker","volume":"127","author":"Sun","year":"2018","journal-title":"Chromosoma"},{"key":"key20260514105755_b22-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2019.01.011","article-title":"Ki-67 protein as a tumour proliferation marker","volume":"491","author":"Menon","year":"2019","journal-title":"Clin Chim Acta"},{"key":"key20260514105755_b23-ol-31-6-15612","first-page":"590","article-title":"Efficacy analysis of PD-1\/PD-L1 inhibitors in the treatment of advanced primary pulmonary lymphoepithelioma-like carcinoma: 6 case reports and literature review","volume":"46","author":"Zhang","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"key20260514105755_b24-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/pathogens7030063","article-title":"Epstein-Barr Virus-induced epigenetic pathogenesis of Viral-associated Lymphoepithelioma-like carcinomas and natural Killer\/T-cell lymphomas","volume":"7","author":"Li","year":"2018","journal-title":"Pathogens"},{"key":"key20260514105755_b25-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s42003-025-07819-0","article-title":"Single-cell analysis reveals transcriptomic features and therapeutic targets in primary pulmonary lymphoepithelioma-like carcinoma","volume":"8","author":"Tan","year":"2025","journal-title":"Commun Biol"},{"key":"key20260514105755_b26-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"7876","DOI":"10.12998\/wjcc.v11.i32.7876","article-title":"Primary pulmonary lymphoepithelioma-like carcinoma misdiagnosed as lung squamous cell carcinoma: A case report","volume":"11","author":"Yin","year":"2023","journal-title":"World J Clin Cases"},{"key":"key20260514105755_b27-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12957-024-03617-w","article-title":"Neoadjuvant immunochemotherapy-a promising strategy for primary pulmonary lymphoepithelioma-like carcinoma","volume":"22","author":"Chen","year":"2024","journal-title":"World J Surg Oncol"},{"key":"key20260514105755_b28-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.7150\/jca.56397","article-title":"Integrating pre- and post-treatment plasma Epstein-Barr virus DNA levels for better prognostic prediction of Nasopharyngeal Carcinoma","volume":"9","author":"Li","year":"2021","journal-title":"J Cancer"},{"key":"key20260514105755_b29-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"e0240729","DOI":"10.1371\/journal.pone.0240729","article-title":"The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis","volume":"15","author":"Tang","year":"2020","journal-title":"PLoS One"},{"key":"key20260514105755_b30-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4103\/jcrt.jcrt_2711_22","article-title":"Comparison of first-line immunotherapy efficacy between advanced lung squamous cell carcinoma and pulmonary lymphoepithelioma-like carcinoma: A propensity score matching multicenter study","volume":"19","author":"Zhou","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"key20260514105755_b31-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"925236","DOI":"10.3389\/fonc.2022.925236","article-title":"Penpulimab for relapsed or refractory classical Hodgkin lymphoma: A multicenter, Single-Arm, pivotal phase I\/II Trial (AK105-201)","volume":"12","author":"Song","year":"2022","journal-title":"Front Oncol"},{"key":"key20260514105755_b32-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"924542","DOI":"10.3389\/fimmu.2022.924542","article-title":"Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 antibody, with improved efficacy and low incidence of Immune-Related adverse events","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"key20260514105755_b33-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"2014296","DOI":"10.1080\/19420862.2021.2014296","article-title":"Antibodies to watch in 2022","volume":"14","author":"Kaplon","year":"2022","journal-title":"MAbs"},{"key":"key20260514105755_b34-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/S1556-0864(21)01938-9","article-title":"Sintilimab plus platinum and gemcitabine as First-Line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, Double-blind, Phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20260514105755_b35-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.lungcan.2022.12.019","article-title":"Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study","volume":"176","author":"Tamiya","year":"2023","journal-title":"Lung Cancer"},{"key":"key20260514105755_b36-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-14-2662","article-title":"KRAS as a therapeutic target","volume":"21","author":"McCormick","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20260514105755_b37-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"2441499","DOI":"10.1080\/15384047.2024.2441499","article-title":"First-line treatments for KRAS-mutant non-small cell lung cancer: Current state and future perspectives","volume":"26","author":"He","year":"2025","journal-title":"Cancer Biol Ther"},{"key":"key20260514105755_b38-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"LBA8511","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8511","article-title":"KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC","volume":"42","author":"Gregorc","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260514105755_b39-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"8510","DOI":"10.1200\/JCO.2024.42.16_suppl.8510","article-title":"Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC","volume":"42","author":"Burns","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260514105755_b40-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: A phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat Med"},{"key":"key20260514105755_b41-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"key20260514105755_b42-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/JIR.S502286","article-title":"A Novel Inflammation-Marker-Based prognostic model for advanced pulmonary Lymphoepithelioma-Like carcinoma","volume":"18","author":"Chen","year":"2025","journal-title":"J Inflamm Res"},{"key":"key20260514105755_b43-ol-31-6-15612","doi-asserted-by":"publisher","first-page":"17588359251316099","DOI":"10.1177\/17588359251316099","article-title":"Efficacy and safety of immunotherapy in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: A multicenter retrospective study","volume":"17","author":"Yang","year":"2025","journal-title":"Ther Adv Med Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:58:04Z","timestamp":1778745484000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15612","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}